Living with Alzheimer's disease is a journey of uncertainty. To find better ways to help patients, researchers need to pinpoint exactly what is going wrong in the brain. A new analysis used a method called multiomic data integration to look at different types of cells in the brain, including neurons and astrocytes.
This analysis found shared problems in these cells, specifically a breakdown in how they produce energy. It also identified specific pathways, like Wnt signaling, that are unique to certain cells. By mapping these specific signatures, the study highlights exactly where the disease is taking hold in the early stages.
Based on these findings, the study identified several drugs that are already being studied or could be repurposed for Alzheimer's. These include guanfacine, as well as eltromobag and encorafenib, which were not previously prioritized. While these are promising targets for future research, it is important to remember that these are computational findings, not results from clinical trials on people.
